EIKN — Eikon Therapeutics, Inc.

—
Nasdaq · Health Care · Biotechnology · CIK 1861123 ·
Last close
$5.15
Market Cap
$279.06M
52W High
$17.40
52W Low
$4.95
ADV30
541,008
Next earnings
2026-11-12
Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs. Its products include EIK1001, a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant; EIK1004 to address brain metastases and primary brain malignancies; EIK1005, a potent WRN helicase inhibitor and anti-tumor agent for MSI-high tumors; and EIK1006, a clinical candidate and next-generation androgen receptor antagonist with activity against multiple clinically emergent variants of androgen receptor. The company was incorporated in 2019 and is based in Millbrae, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -90,552,000 -86,112,000 706,201,000 98,482,000 321,908,000
Jun 2026 0 — -93,394,000 -88,409,000 779,570,000 142,613,000 313,070,000
Mar 2026 0 — -87,337,000 -82,958,000 850,826,000 161,154,000 300,155,000
Dec 2025 0 — -83,168,000 -79,655,000 594,734,000 104,901,000 1,473,768,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-256,018,000
Investing CF
$-88,401,000
Financing CF
$350,633,000
CapEx
$-3,180,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-8.32
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,091,876,000
Inventory
—
Receivables
—
ST Investments
$388,565,000
EBIT TTM
$-323,116,000
Pretax Income TTM
$-322,161,000
Interest Exp TTM
$-48,000
Analysts
6

Annual Trend (SEC EDGAR, last 3y)

Revenues vs Net Income (last 3y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -338,945,000 -324,248,000 594,734,000 1,473,768,000 -879,034,000 -188,516,000
Dec 2024 0 -260,343,000 -243,814,000 491,240,000 1,063,170,000 -571,930,000 -134,799,000
Dec 2023 0 -265,737,000 -241,997,000 525,705,000 867,078,000 -341,373,000 -190,848,000

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
$779,570,000
Forward EPS
$-6.44

Peers — same industry

TickerNameMarket CapLastDaily %
AGEN AGENUS INC $280.98M $6.21 —
EDIT Editas Medicine, Inc. $281.67M $1.83 —
TRXB TRex Bio, Inc. $274.46M $10.00 —
AUTL Autolus Therapeutics plc $290.12M $1.09 —
AGMB AgomAb Therapeutics NV $291.55M $5.92 —

News headlines (Yahoo Finance, 1h cache)

Eikon Therapeutics Announces Clearance to Proceed with First-in-Human Phase 1/2 Study for Novel Androgen Receptor Antagonist EIK1006 in Advanced Metastatic Prostate Cancer
2026-11-17 11:00 · Yahoo
Eikon Therapeutics Reports Third Quarter 2026 Financial Results and Provides Clinical Updates
2026-11-12 11:30 · Yahoo
Eikon Therapeutics Eyes 2027 Melanoma Trial Update, With Key Cancer Data Expected in 2029
2026-11-07 00:14 · Yahoo
Eikon Therapeutics to Participate in Multiple Investor Conferences in November
2026-11-02 14:15 · Yahoo
Eikon Therapeutics Presents Updated EIK1001 Data from TeLuRide-005 at the European Society for Medical Oncology Congress
2026-10-26 10:00 · Yahoo
Eikon Therapeutics Presents Data from PARP1-Selective and WRN Helicase Programs at the European Society for Medical Oncology Congress
2026-10-23 13:15 · Yahoo
Eikon Therapeutics Announces Availability of Seven Abstracts for Presentation at the European Society for Medical Oncology Congress
2026-10-18 22:05 · Yahoo
Eikon Therapeutics Submits IND for Novel Androgen Receptor Antagonist EIK1006 in Prostate Cancer
2026-10-15 12:00 · Yahoo
Eikon Therapeutics Appoints Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer
2026-09-03 11:30 · Yahoo
Eikon Therapeutics Eyes Safer PARP1 Cancer Treatments With EIK1003, EIK1004
2026-08-22 11:01 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.